Veru (NASDAQ:VERU) Posts Earnings Results, Beats Expectations By $0.05 EPS

Key Points

• Veru Inc. reported quarterly earnings of ($0.50) per share, exceeding analysts' expectations of ($0.55) by $0.05.
• Despite the earnings beat, Veru's stock fell $0.42 during mid-day trading, reaching a price of $3.17.
• Veru, categorized as a late clinical stage biopharmaceutical company, is focused on developing treatments for metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS).

Veru (NASDAQ:VERU - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.50) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.05, Zacks reports.

Veru Stock Performance

Shares of NASDAQ VERU traded down $0.42 during mid-day trading on Tuesday, reaching $3.17. 646,629 shares of the company traded hands, compared to its average volume of 277,808. The stock has a market cap of $464.66 million, a PE ratio of -13.21 and a beta of -0.72. The company's fifty day moving average is $5.72 and its two-hundred day moving average is $5.47. Veru has a fifty-two week low of $2.64 and a fifty-two week high of $14.20.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.